Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease

The Mouse Brain in Stereotaxic Coordinates

Paxinos, G. (2001) · Cited by 12,859 · see citing works

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · see citing works

mouse brain in stereotaxic coordinates

Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258 · see citing works

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073 · see citing works

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055 · see citing works

Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation

Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188 · see citing works

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287 · see citing works

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,056 · see citing works

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026 · see citing works

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885 · see citing works

Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids

McGeer, E. G., & McGeer, P. L. (1976) · Nature · doi:10.1038/263517a0 · Cited by 836 · see citing works

Mitochondrial defect in Huntington's disease caudate nucleus

Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · see citing works

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May;8(5):943]

Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 755 · see citing works

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease

Luthi‐Carter, R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.9.1259 · Cited by 723 · see citing works

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Ona, V. O., Li, M., Vonsattel, J. P., Andrews, L. J., Khan, S. Q., Chung, W. M., Frey, A. S., Menon, A., Li, X., Stieg, P. E., et al. (1999) · Nature · doi:10.1038/20446 · Cited by 640 · see citing works

Coenzyme Q ₁₀ administration increases brain mitochondrial concentrations and exerts neuroprotective effects

Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557 · see citing works

Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization

Sawa, A., Wiegand, G. W., Cooper, J. K., Margolis, R. L., Sharp, A. H., Lawler, J. F., Greenamyre, J. T., Snyder, S. H., & Ross, C. A. (1999) · Nature Medicine · doi:10.1038/13518 · Cited by 552 · see citing works

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522 · see citing works

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.

Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485 · see citing works

Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy

Jenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479 · see citing works

Energetics in the pathogenesis of neurodegenerative diseases

Beal, M. F. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01584-8 · Cited by 472 · see citing works

Energy metabolism defects in Huntington's disease and effects of coenzyme Q₁₀

Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405 · see citing works

Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1

Lin, X., Antalffy, B., Kang, D., Orr, H. T., & Zoghbi, H. Y. (2000) · Nature Neuroscience · doi:10.1038/72101 · Cited by 374 · see citing works

Huntington aggregates may not predict neuronal death in Huntington's disease.

Kuemmerle, S., Gutekunst, C., Klein, A., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · PubMed · Cited by 362 · see citing works

A randomized, placebo-controlled trial of coenzyme Q ₁₀ and remacemide in Huntington’s disease

The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312 · see citing works

Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate

Beal, M. F., Brouillet, E., Jenkins, B. G., Henshaw, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03633.x · Cited by 297 · see citing works

An analysis of the role of coenzyme Q in free radical generation and as an antioxidant

Beyer, R. E. (1992) · Biochemistry and Cell Biology · doi:10.1139/o92-061 · Cited by 250 · see citing works

Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization

Ferrante, R. J., Kowall, N. W., Cipolloni, P. B., Storey, E., & Beal, M. F. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1006 · Cited by 244 · see citing works

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

Hansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8727 · Cited by 228 · see citing works

Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum

Greene, J. G., Porter, R. H. P., Eller, R. V., & Greenamyre, J. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03634.x · Cited by 208 · see citing works

Adult-derived neural precursors transplanted into multiple regions in the adult brain

Herrera, D. G., García‐Verdugo, J. M., & Álvarez-Buylla, A. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6 · Cited by 204 · see citing works

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates

Brouillet, M. (1995) · Medical Entomology and Zoology · Cited by 190 · see citing works

Coenzyme Q₁₀ and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate

Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189 · see citing works

Mitochondrial encephalomyopathy (MELAS): Pathological study and successful therapy with coenzyme Q10 and idebenone

Ihara, Y., Namba, R., Kuroda, S., SATO, T. A., & Shirabe, T. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90112-3 · Cited by 161 · see citing works

Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases

Schulz, J. B., Matthews, R. T., Henshaw, D. R., & Beal, M. F. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00527-7 · Cited by 155 · see citing works

Effects of coenzyme Q10 and α-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial α-tocopherol by coenzyme Q10

Lass, A., Forster, M. J., & Sohal, R. S. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00330-x · Cited by 148 · see citing works

Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential

Porter, R. H. P., & Greenamyre, J. T. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020614.x · Cited by 136 · see citing works

Efficacy of unilateral deep brain stimulation of the vim nucleus of the thalamus for essential head tremor

Koller, W. C., Lyons, K. E., Wilkinson, S. B., & Pahwa, R. (1999) · Movement Disorders · doi:10.1002/1531-8257(199909)14:5 · Cited by 132 · see citing works

A controlled trial of remacemide hydrochloride in Huntington's disease

Kieburtz, K. D., Feigin, A., McDermott, M., Como, P. G., Abwender, D. A., Zimmerman, C. F., Hickey, C., Orme, C., Claude, K., Sotack, J., et al. (1996) · Movement Disorders · doi:10.1002/mds.870110310 · Cited by 104 · see citing works

Long‐term coenzyme Q 10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency

Nishikawa, Y., Takahashi, M. M., Yorifuji, S., Nakamura, Y., Ueno, S., Tarui, S., Kozuka, T., & Nishimura, T. (1989) · Neurology · doi:10.1212/wnl.39.3.399 · Cited by 100 · see citing works

[18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies

Antoine, J.-C. G., Cinotti, L., Tilikete, C., Bouhour, F., Camdessanch�, J. P., Confavreux, C., Vighetto, A., Renault‐Mannel, V., Michel, D., & Honnorat, J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 86 · see citing works

Relations Between Tocopherol Depletion and Coenzyme Q During Lipid Peroxidation in rat Liver Mitochondria

Noack, H., Kube, U., & Augustin, W. (1994) · Free Radical Research · doi:10.3109/10715769409145637 · Cited by 81 · see citing works

Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)

Abe, K., Fujimura, H., Nishikawa, Y., Yorifuji, S., Mezaki, T., Hirono, N., Nishitani, N., & Kameyama, M. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb03962.x · Cited by 76 · see citing works

Remacemide Hydrochloride

Dyker, A. G., & Lees, K. R. (1999) · Stroke · doi:10.1161/01.str.30.9.1796 · Cited by 46 · see citing works

Antiglutamate therapies in Huntington’s disease

Kieburtz, K. D. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6369-6_9 · Cited by 44 · see citing works

Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat

Bannan, P. E., Graham, D. I., Lees, K. R., & McCulloch, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)91984-4 · Cited by 40 · see citing works

Effect of coenzyme Q10 on biochemical and morphological changes in experimental ischemia in the rat brain

Ostrowski, R. P. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00406-8 · Cited by 36 · see citing works

N‐Methyl‐ d ‐Aspartate‐ or Glutamate‐Mediated Toxicity in Cultured Rat Cortical Neurons Is Antagonized by FPL 15896AR

Black, M. A., Tremblay, R. G., Mealing, G. A. R., RAY, R. K., Durkin, J. P., Whitfield, J. F., Blosser, J. C., & Morley, P. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052170.x · Cited by 34 · see citing works

ARL-15896, a NovelN-Methyl-D-aspartate Receptor Ion Channel Antagonist: Neuroprotection against Mitochondrial Metabolic Toxicity and Regional Pharmacology

Greene, J. G., Porter, R. H. P., & Greenamyre, J. T. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0007 · Cited by 23 · see citing works

Adenylate cyclase activity in chick retina

Schwarcz, R. M., & Coyle, J. T. (1976) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(76)90019-7 · Cited by 18 · see citing works

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · see citing works

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · see citing works

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi‐Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 847 · see citing works

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

Ferrante, R. J., Kubilus, J. K., Lee, J.-H., Ryu, H., Beesen, A. A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi‐Carter, R., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09418.2003 · Cited by 694 · see citing works

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · see citing works

Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic StrategiesPreprint

Jiménez-Sánchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 512 · see citing works

Excitotoxic and Excitoprotective Mechanisms: Abundant Targets for the Prevention and Treatment of Neurodegenerative Disorders

Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 475 · see citing works

Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease

Gárdián, G., Browne, S. E., Choi, D., Klivènyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B. C., Ratan, R. R., Ferrante, R. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410210200 · Cited by 456 · see citing works

Minocycline and Neurodegenerative Diseases

Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447 · see citing works

Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases

Trushina, E. V., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 440 · see citing works

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin

Okamoto, S., Pouladi, M. A., Talantova, M. V., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.2056 · Cited by 439 · see citing works

Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease?

de Vries, H. E., Witte, M. E., Hondius, D., Rozemüller, A. J. M., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 432 · see citing works

Mitochondrial Diseases of the Brain

Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 416 · see citing works

Huntington's disease: from pathology and genetics to potential therapies

Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409 · see citing works

Redox Signaling by Reactive Electrophiles and Oxidants

Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 357 · see citing works

Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease

Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., Martín‐Ibáñez, R., Muñoz, M. T., Mengod, G., Ernfors, P., & Alberch, J. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1197-04.2004 · Cited by 345 · see citing works

Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice

Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339 · see citing works

Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

Dedeoglu, A., Kubilus, J. K., Jeitner, T. M., Matson, S. A., Bogdanov, M., Kowall, N. W., Matson, W. R., Cooper, A. J. L., Ratan, R. R., Beal, M. F., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08942.2002 · Cited by 317 · see citing works

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease

Keene, C. D., Rodrigues, C. M. P., Eich, T., Chhabra, M. S., Steer, C. J., & Low, W. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362299 · Cited by 306 · see citing works

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · see citing works

Mitochondria in Huntington's disease

Damiano, M. G., Galvan, L., Déglon, N., & Brouillet, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 282 · see citing works

Weight loss in early stage of Huntington’s disease

Djoussé, L., Knowlton, B. A., Cupples, L. A., Marder, K. S., Shoulson, I., & Myers, R. H. (2002) · Neurology · doi:10.1212/01.wnl.0000031791.10922.cf · Cited by 284 · see citing works

Reactive Oxygen Species: Stuck in the Middle of Neurodegeneration

Patten, D. A., Germain, M., Kelly, M., & Slack, R. S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100498 · Cited by 280 · see citing works

Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment

Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 276 · see citing works

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions

Slow, E., Graham, R. K., Osmand, A. P., Devon, R. S., Lu, G., Deng, Y. L., Pearson, J., Vaid, K., Bissada, N., Wetzel, R. B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503634102 · Cited by 273 · see citing works

Endogenous synthesis of coenzyme Q in eukaryotes

Tran, U. C., & Clarke, C. F. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.007 · Cited by 266 · see citing works

Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease

Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., He, L., & Li, X. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02193.2003 · Cited by 260 · see citing works

Huntington's disease

Novak, M. J. U., & Tabrizi, S. J. (2010) · BMJ · doi:10.1136/bmj.c3109 · Cited by 255 · see citing works

Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons

Ryu, H., Lee, J.-H., Zaman, K., Kubilis, J., Ferrante, R. J., Ross, B. D., Neve, R. L., & Ratan, R. R. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03597.2003 · Cited by 251 · see citing works

Protection from mitochondrial complex II inhibition <i>in vitro</i> and <i>in vivo</i> by Nrf2-mediated transcription

Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247 · see citing works

Antioxidant and bioenergetic coupling between neurons and astrocytes

Fernandez-Fernandez, S., Almeida, A., & Bolaños, J. P. (2012) · Biochemical Journal · doi:10.1042/bj20111943 · Cited by 247 · see citing works

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice

Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Signore, S. J. D., Guélin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 246 · see citing works

The Energetics of Huntington's Disease

Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240 · see citing works

Bioenergetic approaches for neuroprotection in Parkinson's disease

Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236 · see citing works

Mismatch repair gene Msh2 modifies the timing of early disease in HdhQ111 striatum

Wheeler, V. C. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg056 · Cited by 232 · see citing works

Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 232 · see citing works

Huntington's Disease: Can Mice Lead the Way to Treatment?

Crook, Z. R., & Housman, D. E. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 229 · see citing works

Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies

Borrell-Pagés, M., Zala, D., Humbert, S., & Saudou, F. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6242-0 · Cited by 224 · see citing works

Experimental therapeutics in transgenic mouse models of Huntington's disease

Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 224 · see citing works

A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease

The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 219 · see citing works

Neurobehavioral assessment in the information age

Tecott, L. H., & Nestler, E. J. (2004) · Nature Neuroscience · doi:10.1038/nn1225 · Cited by 218 · see citing works

Excitotoxic Neuronal Death and the Pathogenesis of Huntington's Disease

Estrada‐Sánchez, A. M., Mejía-Toiber, J., & Massieu, L. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.11.011 · Cited by 213 · see citing works

The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

Li, J. Y., Popović, N., & Brundin, P. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.447 · Cited by 211 · see citing works

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

Klivènyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02160.x · Cited by 201 · see citing works

Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease

Ferrante, R. J., Ryu, H., Kubilus, J. K., D’Mello, S. R., Sugars, K. L., Lee, J.-H., Lu, P., Smith, K., Browne, S. E., Beal, M. F., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.2599-04.2004 · Cited by 195 · see citing works

Coenzyme Q10 effects in neurodegenerative disease

Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 188 · see citing works

The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity

Wang, X., Sirianni, A. C., Pei, Z., Cormier, K., Smith, K., Jiang, J., Zhou, S., Wang, H., Zhao, R., Yano, H., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3059-11.2011 · Cited by 186 · see citing works

Coenzyme Q10 Inhibits Glutamate Excitotoxicity and Oxidative Stress–Mediated Mitochondrial Alteration in a Mouse Model of Glaucoma

Lee, D.-W., Shim, M. S., Keun-young Kim, A., Noh, Y. H., Kim, H., Kim, S. Y., Weinreb, R. N., & Ju, W. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12564 · Cited by 182 · see citing works

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies

Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178 · see citing works

Increased Susceptibility of Striatal Mitochondria to Calcium-Induced Permeability Transition

Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M., & Dubinsky, J. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04858.2003 · Cited by 176 · see citing works

Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models

Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176 · see citing works

Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation

Shao, J., Welch, W. J., DiProspero, N. A., & Diamond, M. I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-08 · Cited by 171 · see citing works

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

Smith, D. L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi‐Noori, S., Lowden, P. A. S., Bates, G. P., & Hockly, E. (2003) · Annals of Neurology · doi:10.1002/ana.10614 · Cited by 173 · see citing works

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 171 · see citing works

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · see citing works

Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 167 · see citing works

Therapeutic Advances for Huntington’s Disease

Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 166 · see citing works

Coenzyme Q10 Decreases Amyloid Pathology and Improves Behavior in a Transgenic Mouse Model of Alzheimer's Disease

Dumont, M., Kipiani, K., Yu, F., Wille, E. J., Katz, M., Calingasan, N. Y., Gouras, G. K., Lin, M. T. S., & Beal, M. F. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110209 · Cited by 161 · see citing works

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease

Johri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 161 · see citing works

Antioxidants in Huntington's disease

Johri, A., & Beal, M. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.014 · Cited by 158 · see citing works

From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research

Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613021 · Cited by 168 · see citing works

Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism

Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158 · see citing works

Clinical Potential of Minocycline for Neurodegenerative Disorders

BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157 · see citing works

Gene expression in Huntington's disease skeletal muscle: a potential biomarker

Strand, A. D., Aragaki, A. K., Shaw, D., Bird, T. D., Holton, J. L., Turner, C., Tapscott, S. J., Tabrizi, S. J., Schapira, A. H. V., Kooperberg, C. L., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi192 · Cited by 160 · see citing works

Assessment of the nutrition status of patients with Huntington's disease

Contreras, A. T., Tarrats, R. M., Alonso, M. E., Boll, M., Ochoa, A., & Velásquez, L. (2004) · Nutrition · doi:10.1016/j.nut.2003.10.007 · Cited by 156 · see citing works

Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?

Takahashi, T., Katada, S., & Onodera, O. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq005 · Cited by 151 · see citing works

Rodent genetic models of Huntington disease

Heng, M. Y., Detloff, P. J., & Albin, R. L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.06.005 · Cited by 149 · see citing works

Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3‐Nitropropionic Acid‐Induced Rat Model of Huntington's Disease

Chakraborty, J., Singh, R. P., Dutta, D., Naskar, A., Rajamma, U., & Mohanakumar, K. P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12189 · Cited by 145 · see citing works

A Small Molecule TrkB Ligand Reduces Motor Impairment and Neuropathology in R6/2 and BACHD Mouse Models of Huntington's Disease

Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M., & Longo, F. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1310-13.2013 · Cited by 145 · see citing works

Inhibition of oxidative stress by coenzyme Q10 increases mitochondrial mass and improves bioenergetic function in optic nerve head astrocytes

Noh, Y. H., Kim, K., Shim, M. S., Choi, S.-H., Choi, S., Ellisman, M. H., Weinreb, R. N., Perkins, G. A., & Ju, W.-K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.341 · Cited by 146 · see citing works

Retinal Damage Caused by High Intraocular Pressure–Induced Transient Ischemia is Prevented by Coenzyme Q10 in Rat

Nucci, C., Tartaglione, R., Cerulli, A., Mancino, R., Spanò, A., Cavaliere, F., Rombolà, L., Bagetta, G., Corasaniti, M. T., & Morrone, L. A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82022-8 · Cited by 143 · see citing works

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

McGarry, A. J., McDermott, M., Kieburtz, K. D., de Blieck, E. A., Beal, F. M., Marder, K. S., Ross, C. A., Shoulson, I., Gilbert, P. R., Mallonee, W. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003478 · Cited by 139 · see citing works

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139 · see citing works

Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice

Pouladi, M. A., Stanek, L. M., Xie, Y., Franciosi, S., Southwell, A. L., Deng, Y., Butland, S. L., Zhang, W., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds037 · Cited by 138 · see citing works

Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III

Solans, A., Zambrano, A., Rodríguez, M., & Barrientos, A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl248 · Cited by 137 · see citing works

Therapeutic use of coenzyme Q 10 and coenzyme Q 10 -related compounds and formulations

Villalba, J. M., Parrado‐Fernández, C., González, M. S., & Alcain, F. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727495 · Cited by 134 · see citing works

Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease

Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136 · see citing works

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127 · see citing works

Pathophysiology of Huntingtonʼs disease: from huntingtin functions to potential treatments

Roze, E. F., Saudou, F., & Caboche, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328304b692 · Cited by 127 · see citing works

Mitochondria as targets for chemotherapy

Gogvadze, V. G., Orrenius, S., & Zhivotovsky, B. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0323-0 · Cited by 125 · see citing works

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease

Zhang, H., Li, Q., Graham, R. K., Slow, E., Hayden, M. R., & Борисович, Б. И. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.03.010 · Cited by 123 · see citing works

Huntington disease

(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122 · see citing works

Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease

Shehadeh, J., Fernandes, H. B., Mullins, M. Z., Graham, R. K., Leavitt, B. R., Hayden, M. R., & Raymond, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.001 · Cited by 120 · see citing works

Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications☆

Bolaños, J. P., Moro, M. Á., Lizasoaín, I., & Almeida, Á. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.009 · Cited by 119 · see citing works

Oxidative stress in Niemann–Pick disease, type C

Fu, R., Yanjanin, N. M., Bianconi, S. E., Pavan, W. J., & Porter, F. D. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.06.018 · Cited by 117 · see citing works

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114 · see citing works

Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease

Zádori, D., Nyíri, G., Szőnyi, A., Szatmári, I., Fülöp, F., Toldi, J., Freund, T. F., Vécsei, L., & Klivènyi, P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0573-6 · Cited by 112 · see citing works

Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases

Martinelli, C., Pucci, C., Battaglini, M., Marino, A., & Ciofani, G. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901589 · Cited by 111 · see citing works

A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse

Chopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W. R., Waldmeier, P. C., Housman, D. E., Kazantsev, A. G., Young, A. B., & Hersch, S. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707842104 · Cited by 108 · see citing works

Environmental factors as modulators of neurodegeneration: Insights from gene–environment interactions in Huntington's disease

Mo, C., Hannan, A. J., & Renoir, T. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.003 · Cited by 103 · see citing works

Huntington Disease and the Huntingtin Protein

Zheng, Z., & Diamond, M. I. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00010-2 · Cited by 104 · see citing works

Excitotoxicity as a Target Against Neurodegenerative Processes

Binvignat, O., & Olloquequi, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200113162641 · Cited by 100 · see citing works

Mouse models of Huntington disease: variations on a theme

Ehrnhoefer, D. E., Butland, S. L., Pouladi, M. A., & Hayden, M. R. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002451 · Cited by 100 · see citing works

Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction

Giralt, A., Carretón, O., Lao‐Peregrín, C., Martín, E. D., & Alberch, J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-71 · Cited by 100 · see citing works

Huntington's Disease

MacDonald, M. E., Ginés, S., Gusella, J. F., & Wheeler, V. C. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:7 · Cited by 100 · see citing works

The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?

Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101 · see citing works

Spinocerebellar Ataxia Type 2: Clinical Presentation, Molecular Mechanisms, and Therapeutic Perspectives

Magaña, J. J., Velázquez‐Pérez, L., & Cisneros, B. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8348-8 · Cited by 97 · see citing works

Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease

Wadsworth, T. L., Bishop, J. A., Pappu, A. S., Woltjer, R. L., & Quinn, J. F. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14210 · Cited by 97 · see citing works

Modelling brain diseases in mice: the challenges of design and analysis

Watase, K., & Zoghbi, H. Y. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1045 · Cited by 94 · see citing works

Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain

Manzar, H., Abdulhussein, D., Yap, T. E., & Cordeiro, M. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239299 · Cited by 94 · see citing works

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151 · see citing works

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127 · see citing works

A randomized, placebo-controlled trial of coenzyme Q ₁₀ and remacemide in Huntington’s disease

The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312 · see citing works

Targeting energy metabolism in Huntington's disease

Walker, F. O., & Raymond, L. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16739-1 · Cited by 21 · see citing works

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114 · see citing works